Latest news and press releases about CervoMed Inc. (CRVO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Price
| Price | $2.44 |
| Market Cap | $23M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.09 |
| EV / EBITDA | -0.03 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -156.02% |
| Return on Invested Capital | -135.73% |
| Return on Assets | -116.76% |
| Gross Margin | 100.00% |
| Operating Margin | -9661.43% |
| Net Margin | -9408.76% |
Related companies: ACET · ADAG · FBIO · GANX · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of CRVO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks